668P - Efficacy of radiofrequency ablation in metastatic liver tumors with gastric origin

Date 29 September 2014
Event ESMO 2014
Session Poster Display session
Topics Hepatobiliary Cancers
Surgical Oncology
Radiation Oncology
Presenter Ghasem Janbabai
Citation Annals of Oncology (2014) 25 (suppl_4): iv210-iv253. 10.1093/annonc/mdu334
Authors G. Janbabai1, H. Shahabandaz2, Y. Sakhaei2, R. Abdi2, M. Teimourzadeh3, S. Borhani1
  • 1Cancer Research Center, Mazandaran University of Medical Sciences, 4816633131 - sari/IR
  • 2Department Of Radiology, Imam Khomeini Hospital, Mazandaran University of Medical Sciences, 4816633131 - sari/IR
  • 3Internal Medicine Department, Mazandaran University of Medical Sciences, 4718865186 - Qaemshahr/IR



Gastric cancer is the second most common cause of death from cancer in Asia .The past 5 years; it was the most common metastatic cancer of the liver in the north of Iran. Radiofrequency ablation (RFA) is a new therapeutic method for liver metastasis which few studies have evaluated its efficacy on liver metastasis originated in the gastric cancer.


In this randomized clinical trial, 43 patients with metastatic lesions from gastric origin enrolled. The number of lesions was less than 5 and their size smaller than 5cm.The gastric cancer patients who confirmed liver metastasis were randomly assigned to received chemotherapy and RFA (group A) or chemotherapy only (group B). Finally, the patients were assessed regarding changes in tumor size and contrast enhancement in MRI.


This study Included 26 males and 17 females, the mean age was 62.51 ± 12.12 years. There was no significant difference between the two groups in age and gender (P = 0.66, P = 0.76). In 93.02% of all patients, metastasis involved the right hepatic lob. The mean size of metastases was 2.96 ± 1.14cm and 3.01 ± 0.96cm in group A and B, respectively (P = 0.83). 14 patients from 21cases in group A (66.6%) were completely lesion free; but in group B there was not any lesion free cases (P < 0.001). In group A, lesion smaller than 3 cm responded better to treatment (P = 0.014).


Our survey shows that RFA is a safe and effective treatment in comparison to conventional chemotherapy for liver metastasis from gastric adenocarcinoma; and the therapeutic effect of chemotherapy in combination with RFA is more than systemic chemotherapy alone, especially in lesion smaller than 3cm.


All authors have declared no conflicts of interest.